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Iron is an essential but potentially hazardous biometal.
Mammalian cells require sufﬁcient amounts of iron to satisfy
metabolic needs or to accomplish specialized functions. Iron is
delivered to tissues by circulating transferrin, a transporter that
captures iron released into the plasma mainly from intestinal
enterocytes or reticuloendothelial macrophages. The binding of
iron-laden transferrin to the cell-surface transferrin receptor 1
results in endocytosis and uptake of the metal cargo. Internalized
iron is transported to mitochondria for the synthesis of haem
or iron–sulfur clusters, which are integral parts of several
metalloproteins, and excess iron is stored and detoxiﬁed in
cytosolic ferritin. Iron metabolism is controlled at different levels
and by diverse mechanisms. The present review summarizes
basic concepts of iron transport, use and storage and focuses on
the IRE (iron-responsive element)/IRP (iron-regulatory protein)
system, a well known post-transcriptional regulatory circuit that
not only maintains iron homoeostasis in various cell types, but
also contributes to systemic iron balance.
Key words: ferritin, ferroportin, iron-regulatory protein 1 (IRP1),
iron-regulatory protein 2 (IRP2), iron–sulfur cluster (ISC),
transferrin receptor (TfR).
BIOCHEMISTRY AND PHYSIOLOGY OF IRON
With minor exceptions, almost all cells employ iron as a cofactor
for fundamental biochemical activities, such as oxygen transport,
energy metabolism and DNA synthesis. This is due to the
ﬂexible coordination chemistry and redox reactivity of iron,
which allow it to associate with proteins and bind to oxygen,
transfer electrons or mediate catalytic reactions [1]. However,
iron is also potentially toxic, because, under aerobic conditions,
it catalyses the propagation of ROS (reactive oxygen species) and
the generation of highly reactive radicals (such as the hydroxyl
radical) through Fenton chemistry [2]. As iron readily shuttles
between the reduced ferrous (Fe
2+) and the oxidized ferric (Fe
3+)
forms, disruption of the cellular redox equilibrium requires only
catalytic amounts of the metal. The ensuing oxidative stress is
associated with damage of cellular macromolecules, tissue injury
and disease [3,4]. It should also be noted that oxidized Fe
3+ is
poorly bioavailable, despite its high abundance, due to limited
solubility. Thus the acquisition, usage and detoxiﬁcation of iron
pose a considerable challenge to cells and organisms, which have
evolvedsophisticatedmechanismstosatisfytheirmetabolicneeds
and concomitantly minimize the risk of toxicity [5–7].
The vast majority of body iron (at least 2.1 g in humans) is
distributed in the haemoglobin of red blood cells and developing
erythroidcellsandservesinoxygentransport.Signiﬁcantamounts
of iron are also present in macrophages (up to 600 mg) and in
the myoglobin of muscles (∼300 mg), whereas excess body iron
(∼1 g) is stored in the liver [8,9]. Other tissues contain lower,
but not negligible, quantities of iron. Mammals lose iron from
sloughingofmucosalandskincellsorduringbleeding,butdonot
possessanyregulatedmechanismforironexcretionfromthebody.
Therefore balance is maintained by the tight control of dietary-
iron absorption in the duodenum (Figure 1). The uptake of nu-
tritional iron involves reduction of Fe
3+ in the intestinal lumen
by ferric reductases [such as Dcytb (duodenal cytochrome b)]
and the subsequent transport of Fe
2+ across the apical membrane
of enterocytes by DMT1 (divalent metal transporter 1), a mem-
ber of the SLC (solute carrier) group of membrane transport pro-
teins,alsoknownasSLC11A2.Dietaryhaemcanalsobetranspor-
tedacrosstheapicalmembranebyayetunknownmechanismand
subsequently metabolized in the enterocytes by HO-1 (haem oxy-
genase 1) to liberate Fe
2+. Directly internalized or haem-derived
Fe
2+ is processed by the enterocytes and eventually exported
across the basolateral membrane into the bloodstream via the
solute carrier and Fe
2+ transporter ferroportin (also known as
SLC11A3). The ferroportin-mediated efﬂux of Fe
2+ is coupled
by its re-oxidation to Fe
3+, catalysed by the membrane-bound
ferroxidase hephaestin that physically interacts with ferroportin
[10], and possibly also by its plasma homologue ceruloplasmin.
ExportedironisscavengedbyTf(transferrin),whichmaintains
Fe
3+ in a redox-inert state and delivers it into tissues. The total
iron content of Tf (∼3 mg) corresponds to less than 0.1% of
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Figure 1 Hormonal regulation of iron efﬂux from duodenal enterocytes and reticuloendothelial macrophages by hepcidin
Enterocytes absorb inorganic or haem iron from the diet and macrophages phagocytose iron-loaded senescent red blood cells, or acquire iron by other mechanisms (see the main text). Both cell
types release Fe2+ into the plasma via ferroportin (Fpn), which is incorporated into apo-Tf following oxidation to Fe3+ via hephaestin (Heph) or ceruloplasmin (Cp). Hepatocytes generate the
iron-regulatory hormone hepcidin in response to high iron or inﬂammatory signals, which inhibits the efﬂux of iron via ferroportin and promotes its retention within enterocytes and macrophages.
body iron, but it is highly dynamic and undergoes more than ten
times daily turnover to sustain erythropoiesis. The Tf iron pool is
replenished mostly by iron recycled from effete red blood cells
and, to a lesser extent, by newly absorbed dietary iron. Senescent
red blood cells are cleared by reticuloendothelial macrophages,
whichmetabolizehaemoglobinandhaem,andreleaseironintothe
bloodstream. By analogy to intestinal enterocytes, macrophages
export Fe
2+ from their plasma membrane via ferroportin, in a
process coupled by re-oxidation of Fe
2+ to Fe
3+ by ceruloplasmin
and followed by the loading of Fe
3+ to Tf (Figure 1).
Ferroportinisexpressedinmanyiron-exportingcells,including
placental syncytiotrophoblasts, and plays a fundamental role
in the release of iron from tissues into the bloodstream, but
also in maternal iron transfer to the fetus. The complete
disruption of mouse ferroportin is embryonic lethal, whereas its
conditional inactivation leads to iron retention and accumulation
in enterocytes, macrophages and hepatocytes [11].
REGULATION OF SYSTEMIC IRON TRAFFIC
The ferroportin-mediated efﬂux of Fe
2+ from enterocytes and
macrophages into the plasma is critical for systemic iron
homoeostasis. This process is negatively regulated by hepcidin,
a liver-derived peptide hormone that binds to ferroportin and
promotes its phosphorylation, internalization and lysosomal
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degradation[6,12].Hepcidinisprimarilyexpressedinhepatocytes
as a precursor pro-peptide. Pro-hepcidin undergoes proteolytic
processing to yield a bioactive molecule of 25 amino acids
that is secreted into the bloodstream. Hepcidin accumulates
following iron intake and under inﬂammatory conditions,
resulting in decreased dietary-iron absorption and iron retention
in macrophages (Figure 1); during infection, this very probably
serves to deprive invading bacteria from iron that is essential
for growth. Conversely, hepcidin levels drop in iron deﬁciency,
hypoxia or phlebotomy-induced anaemia, and this response
promotes intestinal iron absorption and iron release from
macrophages. The disruption of hepcidin is associated with
systemic iron overload (haemochromatosis) [13], whereas
pathological elevation of hepcidin levels contributes to the
development of the anaemia of chronic disease [14] and accounts
for the phenotype of hereditary IRIDA (iron-refractory iron
deﬁciency anaemia) [15].
The expression of hepcidin is controlled transcriptionally.
BasalhepcidintranscriptionrequiresC/EBPα(CCAAT/enhancer-
binding protein α) [16]. Iron-dependent induction of hepcidin
requires BMP (bone morphogenetic protein) signalling. Iron
triggers the expression of BMP6 in the liver [17] and the intestine
[18], which is thought to be secreted into the plasma for binding
toaBMPreceptoronthesurfaceofhepatocytes.BMP6signalling
leads to phosphorylation of SMAD1/5/8 and translocation of
SMAD4 to the nucleus, where it promotes hepcidin transcription
upon binding to proximal and distal sites on its promoter. This
model is supported by genetic data with BMP6
−/− [19,20] and
liver-speciﬁcSMAD4
−/− [21]mice,whichdevelopironoverload
and express inappropriately low hepcidin levels. It has also been
proposed that hepcidin responds to increased Tf saturation [22],
possiblybyamechanismrequiringacross-talkbetweenBMPand
MAP (mitogen-activated protein kinase) signalling [23]. Further
cofactors are required for iron-dependent activation of hepcidin,
even though their exact mode of action is not yet clear. These
include the haemochromatosis protein HFE, TfR2 (Tf receptor
2) and the BMP co-receptor HJV (haemojuvelin). Mutations in
these proteins impair hepcidin expression and lead to hereditary
haemochromatosis [13]. The membrane-bound serine protease
matriptase 2 (TMPRSS6) appears to inhibit signalling to hepcidin
by degrading HJV [24]. Mutations in matriptase 2 are associated
with IRIDA, which is caused by hepcidin overexpression [15].
The pro-inﬂammatory cytokine IL-6 (interleukin-6) induces
hepcidin transcription via STAT3 (signal transducer and activator
of transcription 3) phosphorylation and translocation to the
nucleus for binding to a proximal promoter element [25].
IL-1β activates hepcidin via the C/EBPα and BMP/SMAD
pathways [26]. In addition, ER (endoplasmic reticulum)
stress turns on hepcidin transcription via CREBH (cyclic
AMP response element-binding protein H) [27] and/or CHOP
(C/EBP homologous protein) [28]. Lipopolysaccharide promotes
autocrine activation of hepcidin in macrophages via TLR4 (Toll-
like receptor 4) signalling [29], whereas the pathogen Borrelia
burgdorferi activates myeloid hepcidin via TLR2 [30].
Hepcidin transcription is suppressed during anaemia by
a mechanism that requires erythropoietic activity [31]. In
thalassaemic patients, hepcidin expression is blocked upon
induction of GDF15 (growth differentiation factor 15) [32],
am e m b e ro ft h eT G F - β (transforming growth factor β)
superfamily. Likewise, the erythroid regulator TWSG1 (twisted
gastrulation homologue 1) was reported to contribute to hepcidin
suppression in cell-culture experiments and in thalassaemic mice
[33]. EPO (erythropoietin) signalling downregulates hepcidin
following decreased binding of C/EBPα to its promoter [34].
Hepcidin transcription is also suppressed by hypoxia and
oxidative stress. The role of HIFs (hypoxia-inducible factors)
in the hypoxic pathway of hepcidin is debatable [35], whereas
oxidative stress promotes histone deacetylation and decreased
binding of C/EBPα and STAT3 to the hepcidin promoter [36].
There is no doubt that hormonal regulation of iron efﬂux from
cells via the hepcidin/ferroportin axis is of paramount importance
for systemic iron homoeostasis. However, it should be noted that
the expression of ferroportin is also subjected to transcriptional
[37] and post-transcriptional (see below) control. Recent results
showed that hepcidin-dependent degradation of ferroportin
does not sufﬁce to limit dietary-iron absorption in mice lacking
intestinalH-ferritin,addingfurthercomplexitytothemechanisms
for regulation of systemic iron homoeostasis [38]. Along similar
lines, dietary-iron absorption can be induced independently of
the hepcidin pathway by transcriptional activation of DMT1
and Dcytb in duodenal enterocytes, a response orchestrated by
HIF-2α [39,40].
MECHANISMS FOR CELLULAR IRON UPTAKE
The Tf cycle
Developing erythroid cells, as well as most other cell types,
acquire iron from plasma Tf. Iron-loaded holo-Tf binds with high
afﬁnity to TfR1 on the surface of cells [41], and the complex
undergoes endocytosis via clathrin-coated pits (Figure 2). A
proton pump promotes acidiﬁcation of the endosome to pH 5.5,
triggering the release of Fe
3+ from Tf that remains bound to
TfR1. The ferrireductase Steap3 reduces Fe
3+ to Fe
2+ [42], which
is transported across the endosomal membrane by DMT1 to the
cytosol or, possibly, directly to mitochondria in erythroid cells
[43].Followingthereleaseofiron,theafﬁnityofTftoTfR1drops
∼500-fold, resulting in its dissociation. In the ﬁnal step of the
cycle, apo-Tf is secreted into the bloodstream to recapture Fe
3+.
The importance of the Tf cycle for iron delivery into erythroid
cells is underscored by the embryonic lethal erythropoietic
defects associated with the targeted disruption of mouse TfR1,
and the microcytic hypochromic anaemia of TfR1
+/− animals
[44]. Moreover, hpx (hypotransferrinaemic) mice that fail to
express appropriate Tf levels due to a splicing defect also
develop microcytic hypochromic anaemia, which is associated
with paradoxical hepatic iron overload [45]. These ﬁndings
provide strong evidence that the Tf cycle is indispensable for
iron delivery to erythroid cells, and Tf is the only physiological
iron donor for erythropoiesis.
DMT1 does not only account for dietary-iron absorption in
the intestine, but also constitutes a crucial component of the
Tf cycle by mediating Fe
2+ transport across the endosomal
membrane. Thus DMT1
−/− mice can neither absorb dietary
iron, nor efﬁciently use iron for erythropoiesis and, consequently,
develop severeand fatal microcytic hypochromicanaemiashortly
after birth [46]. Animals with partially inactivated mutant DMT1
(mk/mk mice and Belgrade rats) exhibit severe anaemia [47,48].
Other mechanisms for iron uptake
Macrophages may use the Tf cycle for iron uptake, especially
in culture. However, in vivo, resident macrophages acquire high
amounts of iron by phagocytosis of effete red blood cells (Fig-
ure 1). Macrophages also have the capacity to clear haemoglobin
and haem that is released in the circulation during intravascular
hemolysis.FreehaemoglobinisscavengedbyHp(haptoglobin),a
liver-derivedplasmaprotein,whichinturnisinternalizedbymac-
rophagesuponbindingtothereceptorCD163[49].Likewise,free
haem is scavenged by plasma Hpx (haemopexin) and undergoes
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Figure 2 Cellular iron uptake via the Tf cycle
Iron-loadedholo-TfbindstoTfR1onthecellsurfaceandthecomplexundergoesendocytosisviaclathrin-coatedpits.Aprotonpumpacidiﬁestheendosome,resultinginthereleaseofFe3+,whichis
subsequentlyreducedtoFe2+ bySteap3andtransportedacrosstheendosomalmembranetothecytosolbyDMT1.Internalizedironisdirectedtomitochondriaviamitoferrinformetabolicutilization
(such as synthesis of haem and ISCs), and excess iron is stored in ferritin. A cytosolic fraction of redox-active intracellular iron constitutes the LIP. The apo-Tf–TfR1 complex is recycled to the cell
surface, where apo-Tf is released to capture plasma Fe3+.
endocytosis in macrophages upon binding to the receptor
CD91 [50]. Directly internalized haem, or haem derived from
the degradation of haemoglobin following direct haemoglobin
uptake or erythrophagocytosis, is degraded by HO-1, yielding
Fe
2+, which is released into the plasma through ferroportin.
Nramp1 (natural resistance-associated macrophage protein 1),
a homologue of DMT1, contributes to efﬁcient recycling of
haemoglobin iron, especially during haemolytic anaemia [51].
Plasma Tf delivers iron to all tissues, except those that are
separated from the blood by layers of endothelial cells forming
a physical barrier (for example the brain, the testis or the eye).
Howironcrossestheblood–brainandotherbarriers,whichdonot
allowthefreepassageofproteinsandmetabolites,isincompletely
understood. It appears that the endothelial cells at the luminal site
of blood capillaries express TfR1 and take up iron from plasma
Tf [52,53]. The release of iron from endothelial cells (but also
neurons or astrocytes) into the brain interstitium very probably
involves ferroportin in conjunction with a ferroxidase activity,
by analogy to the mechanism for basolateral iron transport
in the intestinal epithelium. The ferroxidase activity can be
provided by ferroportin-interacting proteins such as hephaestin,
GPI(glycosylphosphatidylinositol)–ceruloplasmin(amembrane-
associated ceruloplasmin isoform) [54] or β-APP (β-amyloid
precursorprotein)[55].Insidetheinterstitialﬂuid,ironiscaptured
by brain Tf that is secreted from oligodendrocytes.
Previously, plasma Tf was believed to be spared from
substantial glomerular ﬁltration in the kidney [56]. Later, it
was established that polarized epithelial cells from the renal
proximal tubules may acquire Tf-bound iron via the endocytic
receptor cubilin, which operates in conjunction with its co-
receptor megalin [57]. Cubilin (but not TfR1) is expressed on
the apical (urine-facing) site of proximal tubule cells, which
also contain high levels of endosomal DMT1, suggesting that
at least a fraction of Tf is ﬁltered in the kidney and retrieved
from the glomerular ﬁltrate upon binding to cubilin [56]. It is
conceivable that the efﬂux of iron from the basolateral site of the
proximal tubule cells to the bloodstream may involve ferroportin
and hephaestin/ceruloplasmin.
Lcn2 (lipocalin 2), a mammalian protein that was identiﬁed by
its capacity to interact with the bacterial siderophore enterobactin
[58], is involved in iron-uptake pathways that operate during
kidneydevelopment[59]andinjury[60],andunderinﬂammatory
conditions [61]. Iron-loaded Lcn2 is internalized by the receptors
24p3R [61] and megalin [62]. Siderophores are low-molecular-
mass iron-chelating metabolites, known to be synthesized
by bacteria and fungi to acquire extracellular iron. It was
recently demonstrated that mammals synthesize the siderophore
2,5-DHBA (dihydroxybenzoic acid), which is isomeric
to 2,3-DHBA, the iron-binding component of enterobactin [63].
Importantly,depletionof2,5-DHBAderegulatedironmetabolism
in mammalian cells and zebraﬁsh embryos, highlighting the
biological importance of Lcn2-dependent mechanisms. Lcn2
−/−
mice exhibit apparently normal iron metabolism; however, they
fail to mount efﬁcient innate immune responses against bacterial
infection, suggesting that Lcn2 serves to deprive bacteria of
nutritional iron [64].
c   The Authors Journal compilation c   2011 Biochemical Society © 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.Regulation of cellular iron metabolism 369
Under physiological conditions, plasma Tf is hyposaturated
(to ∼30%) and displays a very high iron-binding capacity, to
preclude the accumulation of unshielded NTBI (non-transferrin-
bound iron). However, in hereditary haemochromatosis and other
iron-overload disorders, the levels of plasma iron exceed the
saturation capacity of Tf, and a pool of NTBI builds up that
contributes signiﬁcantly to hepatic iron loading [65]. The exact
chemical nature of NTBI remains elusive, but its redox reactivity
and toxicity is well established. It may consist of Fe
3+ loosely
chelated by albumin or by small organic molecules, such as
citrate [66]. The mechanisms of NTBI uptake by cells are poorly
understood, but a role for Lcn2 has been excluded [67]. The zinc
transporter Zip14 (also known as SLC39A) appears capable of
mediatingNTBIuptake[68]aswellaspromotingtheassimilation
of Tf-bound iron [69].
Ferritin, the iron-storage protein (see below) has also been
implicated in iron-transport pathways, which may predominate
in pathological states, where iron-rich intracellular ferritin is
released from damaged tissues. The membrane-bound protein
TIM-2 (T-cell immunoglobulin-domain and mucin-domain 2)
functions as a ferritin receptor in rodents [70]. More recently,
it was shown that ferritin can be taken up by Scara 5 (scavenger
receptor5)anddonateirontothedevelopingkidney[71],whereas
H-ferritin can be internalized by cells upon speciﬁc binding to
TfR1 [72].
CELLULAR IRON METABOLISM
Iron usage in mitochondria
Cells mostly use iron in mitochondria for the synthesis of
haem and ISCs (iron–sulfur clusters). The mechanism for
intracellular iron trafﬁcking to mitochondria is incompletely
understood. Kinetic evidenceand microscopy studies in erythroid
cells have provided support for the ‘kiss and run’ hypothesis,
which postulates the direct delivery of Tf-derived iron to
mitochondria through a transient contact with the endosome
[43]. In other cell types, it is generally accepted that iron
acquired during the Tf cycle is ﬁrst released into the cytosol
and then targeted to the mitochondria. The conserved cytosolic
glutaredoxins Grx3 and Grx4 appear to play an essential role
in intracellular iron sensing and trafﬁcking, as their depletion in
yeast leads to impaired iron transport to mitochondria and
defects in iron-dependent pathways [73]. It is also well
established that the entry of iron into mitochondria requires
the SLC transporter mitoferrin (also known as SLC25A37),
which is localized to the inner mitochondrial membrane [74].
Mitoferrin-1 is highly enriched in erythroid cells and is
stabilized during differentiation and following interaction with
the erythroid-speciﬁc ABC transporter Abcb10 (ATP-binding
cassette, subfamily B, member 10) [75], whereas mitoferrin-2
is ubiquitously expressed and its half-life is not regulated [76].
Both mitoferrin isoforms are homologous; however, they exhibit
limited functional redundancy, as overexpression of mitoferrin-2
cannot support mitochondrial iron assimilation in erythroid cells
deﬁcient of mitoferrin-1. The lack of functional mitoferrin-1
in the frs (frascati) zebraﬁsh mutant is associated with severe
defectsinerythropoiesis,haemsynthesisandISCbiogenesis[74].
Interestingly,depletionofthemammaliansiderophore2,5-DHBA
also leads to defects in mitochondrial iron assimilation and haem
synthesis [63], underscoring a role for the Lcn2 pathway in iron
delivery to mitochondria.
All organisms synthesize the tetrapyrrol porphyrin ring of
haem from the universal precursor ALA (5-aminolevulinic
acid) by a conserved eight-step enzymatic pathway [77–79].
Most eukaryotes (except plants), generate ALA in mitochondria
by the condensation of succinyl-CoA and glycine, which
is catalysed by ALAS (ALA synthase). Mammals express
a housekeeping (ALAS1) and an erythroid-speciﬁc (ALAS2)
isoform of this enzyme. The universal precursor ALA is exported
to the cytosol and converted into the intermediate metabolites
porphobilinogen, hydroxymethylbilane, uroporphyrinogen III
and coproporphyrinogen III. The latter is oxidized to
protoporphyrinogen IX and imported into the mitochondria,
where it is further oxidized to protoporphyrin IX. In the
ﬁnal reaction of the haem biosynthetic pathway, ferrochelatase
catalyses the insertion of Fe
2+ into protoporphyrin IX. Newly
synthesized haem is exported to the cytosol for incorporation
into haemoproteins. The transport of haem and its metabolic
intermediates across the mitochondrial membranes may involve
members of the ABC family of transporters [77] and the SLC
transporter SLC25A39 [80]. In non-erythroid cells, the rate-
limiting step of the haem biosynthetic pathway is the synthesis of
ALA. By contrast, the synthesis of the porphyrin ring in erythroid
cells depends on the iron supply, which is rate-limiting [79].
The assembly and repair of ISCs is mediated by complex
pathways. The functions of several proteins of these pathways
have been deﬁned, yet new players continue to emerge [81–83].
The mitochondrial proteins Isu1/2 (also known as ISCU) and
Isa1/2 (also known as ISCA1/2) provide a scaffold for the
early steps of ISC biogenesis. The cysteine desulfurase Nfs1
(nitrogen ﬁxation homologue 1, also known as ISCS), in
complexwithISD11(iron–sulfurproteinbiogenesis,desulfurase-
interacting protein 11), generates elemental sulfur, whereas the
iron-bindingproteinfrataxinappearstoserveasanirondonor.The
mitochondrialproteinsGrx5andthetransporterAbcb7participate
in the maturation of ISCs; however, their mode of action is
not clear. The biogenesis of cytosolic ISC proteins requires
mitochondria-derived ISC precursors, which are processed by
a dedicated CIA (cytosolic ISC assembly) machinery [82]; to
date, various CIA components have been identiﬁed, such as the
P-loop NTPase Cfd1 (cytosolic Fe–S cluster-deﬁcient protein
1), Nar1 (nuclear architecture-related protein 1)/IOP1 (iron-only
hydrogenase-likeprotein1),Cia1,Dre2andTah18.Cfd1interacts
with Nbp35 (nucleotide-binding protein 35) and the complex has
beenproposedtofunctionasascaffoldforcytosolicISCassembly
[84]. An alternative model postulates that the cytosol is equipped
with a complete machinery for de novo ISC assembly, consisting
of cytosolic orthologues of mitochondrial ISC assembly factors
such as Isu/ISCU and Nfs1/ISCS [83]. Importantly, defects in
ISC biogenesis are associated with deregulation of cytosolic and
cellular iron metabolism [43,83].
Handling of excess iron
Cells may eliminate excess intracellular iron by secretion of Fe
2+
via ferroportin or by secretion of haem through the putative haem
exporter FLVCR (feline leukaemia virus, subgroup C, receptor)
[85]. Cells can also store and detoxify excess intracellular iron
in the cytosol within ferritin, a conserved protein consisting of
24 H (heavy) and L (light) subunits, encoded by distinct genes
[86]. Ferritin assembles into a shell-like structure with a cavity
of ∼80 Å (1 Å=0.1 nm) that provides storage space for up
to 4500 Fe
3+ ions in form of ferric oxy-hydroxide phosphate.
Iron may enter ferritin with the aid of PCBP1 [poly(rC)-binding
protein 1], which appears to function as an iron chaperone
[87]. The incorporation of iron into holo-ferritin also requires
the ferroxidase activity of H-ferritin, whereas L-ferritin chains
provide a nucleation centre. The levels of H-ferritin and L-ferritin
differ among various tissues; the former is enriched in the heart
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and the latter in the liver. Intracellular iron deposits may also be
detected within haemosiderin, a structure consisting of ferritin
degradation products and iron oxide clusters.
Iron stored within ferritin is considered to be bioavailable
and may be mobilized for metabolic purposes during its
lysosomal turnover [88] and, possibly, also following dynamic
structural rearrangements of the ferritin subunits [89]. However,
ferritin failed to donate iron for endogenous haem synthesis in
experiments with cultured macrophages [90]. The induction of
ferroportin promotes mobilization and export of ferritin-derived
iron, followed by mono-ubiquitination and degradation of apo-
ferritin by the proteasome [91]. Thus ferritin can be degraded
by two different pathways, the lysosomal and the proteasomal
pathways,whichappearstorequirepriordepletionofitsiron[92].
The iron-storage function of ferritin is crucial for health. Thus the
ablation of the gene encoding H-ferritin leads to early embryonic
lethality [93], whereas the conditional disruption of this gene
promotes liver damage due to oxidative stress [94]. Moreover,
the intestinal disruption of H-ferritin misregulates dietary-iron
absorption[38].Ontheotherhand,mutationsinthegeneencoding
L-ferritinareassociatedwithneuroferritinopathy,ararehereditary
movement disorder with an autosomal dominant transmission
pattern, characterized by accumulation of redox-active iron in
the brain [95].
Mitochondria contain a nuclear-encoded ferritin isoform [96].
Mitochondrial ferritin derives from an unusual intronless gene
and is synthesized in the cytosol as a precursor polypeptide that is
targeted to mitochondria by an N-terminal leader sequence. The
mature protein possesses ferroxidase activity and assembles into
functional ferritin nanocages. Mitochondrial ferritin is normally
expressed at low levels and does not appear to have any major
function in normal mitochondrial iron utilization. Its expression,
however,issigniﬁcantlyinducediniron-loadedringerythroblasts
(sideroblasts) of sideroblastic anaemia patients and may serve as
a sink for iron deposition [97].
A secreted glycosylated isoform of predominantly L-ferritin
circulates in the bloodstream. It contains very low amounts of
iron, suggesting that it does not play an essential role in iron sto-
rage or trafﬁc, but it is used as a clinical marker for body iron
stores. Experiments in mice suggested that serum ferritin derives
from splenic macrophages and kidney proximal tubule cells [98].
LIP (labile iron pool)
Various cell types contain a transient cytosolic pool of iron,
presumably bound to low-molecular-mass intracellular chelates,
such as citrate, various peptides, ATP, AMP or pyrophosphate.
This LIP is redox-active and can be monitored in situ by using
ﬂuorescent sensors such as calcein or Phen Green SK [99,100].
Experiments with other ﬂuorescent sensors that are selective for
mitochondria also suggest the presence of chelatable iron in this
organelle [101]. Ferritin and iron-chelating drugs protect cells
againstoxidativedamagebyreducingthecytosolicLIPincultured
cells[102]andinanimals[103].However,chronicoverexpression
of ferritin may lead to the opposite effect in mice, suggesting
that iron sequestered in the ferritin shells may eventually become
pro-oxidant [104]. The cytosolic LIP mirrors the cellular iron
contentanditsﬂuctuationsareconsideredtotriggerhomoeostatic
adaptive responses.
THE IRE (IRON-RESPONSIVE ELEMENT)/IRP (IRON-REGULATORY
PROTEIN 1) REGULATORY SYSTEM
The expression of TfR1 and ferritin are co-ordinately regulated
post-transcriptionally upon binding of IRP1 or IRP2 to IREs
Figure 3 Typical IRE motif
A typical IRE motif consists of a hexanucleotide loop with the sequence 5 -CAGUGH-3 
(H could be A, C, or U) and a stem, interrupted by a bulge with an unpaired C residue
(left) or an asymmetric tetranucleotide bulge (right); the latter is characteristic of ferritin IRE.
Base-pairing between C1 and G5 of the loop is functionally important.
in the UTRs (untranslated regions) of their respective mRNAs
[105–107]. IREs (Figure 3) are evolutionarily conserved hairpin
structures of 25–30 nt [108]. A typical IRE stem consists of
variable sequences that form base pairs of moderate stability
( G≈−7 kcal/mol), and folds into an α-helix that is slightly
distorted by the presence of a small bulge in the middle
(an unpaired C residue or an asymmetric UGC/C bulge/loop
commonly found in the ferritin IRE). The loop contains a
conserved 5
 -CAGUGH-3
  sequence (H denotes A, C or U),
where the underlined C and G residues form a base pair. TfR1
mRNA contains multiple IREs within its long 3
 UTR, whereas
the mRNAs encoding H- and L-ferritin contain a single IRE in
their 5
 UTRs.
In iron-starved cells, IRPs bind with high afﬁnity (Kd≈10
−12
M) to cognate IREs. The IRE–IRP interactions stabilize TfR1
mRNA and, moreover, impose a steric blockade to ferritin mRNA
translation(Figure4).Asaresult,increasedTfR1levelsstimulate
acquisition of iron from plasma Tf to counteract iron deﬁciency.
The inhibition of de novo ferritin synthesis leads to decreased
abundance of this protein, as iron storage becomes obsolete under
these conditions. Conversely, in cells with high iron content, both
IRP1 and IRP2 become unavailable for IRE binding, allowing
TfR1 mRNA degradation and ferritin mRNA translation. Thus
when iron supply exceeds cellular needs, the IRE–IRP switch
minimizesfurtherironuptakeviaTfR1,andfavoursthestorageof
excess iron in newly synthesized ferritin. The pathophysiological
signiﬁcance of the IRE–IRP system is illustrated in HHCS
(hereditary hyperferritinaemia–cataract syndrome), an autosomal
dominant disorder, characterized by supra-physiological serum
ferritin levels (without iron overload) and early-onset cataract,
that is caused by mutations in L-ferritin IRE that prevent IRP
binding [109].
The IRE–IRP system was initially deﬁned as a relatively
simple and ubiquitous post-transcriptional regulatory circuit
that maintains cellular iron homoeostasis in vertebrates by
orchestrating co-ordinated iron uptake by TfR1 and storage in
ferritin. The identiﬁcation of additional IRE-containing mRNAs
and the ongoing biochemical and physiological characterization
of IRPs added considerable complexity and uncovered a
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Figure 4 Post-transcriptional control of cellular pathways by the IRE–IRP regulatory system
Translational-type IRE–IRP interactions in the 5 UTR modulate the expression of the mRNAs encoding H- and L-ferritin, ALAS2, m-aconitase, ferroportin, HIF-2α, β-APP and α-synuclein, which
in turn control iron storage, erythroid iron utilization, energy homoeostasis, iron efﬂux, hypoxic responses and neurological pathways respectively. Conversely, IRE–IRP interactions in the 3 UTR
stabilize the mRNAs encoding TfR1, DMT1, Cdc14A and MRCKα, which are involved in iron uptake, iron transport, the cell cycle and cytoskeletal remodelling respectively. Note that the regulation
of DMT1, Cdc14A and MRCKα may require additional factors, and that the IREs in Cdc14A and MRCKα mRNAs are not phylogenetically conserved.
functional signiﬁcance for the IRE–IRP system that exceeds the
narrowboundariesofcellularironuptakeandstorage.Limitations
of this system have also been reported, mostly in specialized
cells that may override IRE–IRP-mediated control mechanisms
for efﬁcient iron handling. For example, TfR1 mRNA stability
is uncoupled from iron supply and IRP regulation in erythroid
progenitor cells, which take up extraordinary amounts of iron
for haem synthesis and haemoglobinization [110]; under these
conditions, TfR1 expression is regulated transcriptionally by
an erythroid active element in its promoter [111]. IRE–IRP-
independent regulation of TfR1 and ferritin at the transcriptional
level is well established, and is reviewed elsewhere [112,113].
OTHER IRE-CONTAINING mRNAS
The biochemical characterization of IREs and the establishment
of a canonical IRE motif prepared the way for the discovery of
further IRE-containing mRNAs, some of them bearing atypical,
yet functional, IREs [105–107]. An in silico screen of nucleotide
databases led to the identiﬁcation of a ‘translation-type’ IRE (an
IRE that confers translational regulation) in the 5
 UTR of ALAS2
mRNA. Considering that ALAS2 catalyses the initial reaction for
haem biosynthesis in erythroid cells, the translational repression
of its mRNA by IRPs associates the IRE–IRP system with
systemic iron utilization and homoeostasis. This response may
inhibit the accumulation of toxic protoporphyrin IX when iron is
scarce. The severe hypochromic anaemia and early embryonic
lethality of the sir (shiraz) zebraﬁsh mutant is caused by a
genetic defect in Grx5, which impairs the regulation of IRP1 (see
below) and eventually leads to translational repression of ALAS2
[114].Asimilar,butrelativelymilder,biochemicalphenotypehas
been documented in a human patient with sideroblastic anaemia;
interestingly, ALAS2 mRNA translation was suppressed by both
IRPs because the deregulation of IRP1 was associated with
cytosolicirondepletionandconcomitantinductionofIRP2[115].
A single translation-type IRE was also found in the 5
 UTR of
the mRNAs encoding mammalian m-aconitases (mitochondrial
aconitases) and the Ip (iron protein) subunit of Drosophila
SDH (succinate dehydrogenase), which are both iron–sulfur
enzymes of the citric acid cycle. The latter is not conserved
in SDH transcripts of other insects [108]. Quantitatively, the
degree of IRP-mediated translational repression of mammalian
m-aconitases and Drosophila SDH is not profound (as compared
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withferritin);however,itmaysufﬁcetoco-ordinatetheexpression
of these iron-containing proteins with iron availability and link
the IRE–IRP system with energy metabolism.
The mRNAs encoding the iron transporters DMT1 and
ferroportin are expressed in alternatively spliced isoforms, some
of which are furnished with a translation-type IRE. Two out of
four DMT1 transcripts contain a single IRE in their 3
 UTR
[116] that presumably operates as a stability control element
and accounts for the high duodenal DMT1 expression in iron-
deﬁcient mice [117]. Nevertheless, the function of DMT1 IRE
appears to be cell-speciﬁc and to require additional upstream
regulatory elements in exon 1A [116]. Ferroportin mRNA is
expressed in two alternatively spliced transcripts, one of which
contains a single translation-type IRE in its 5
 UTR [118] that
is consistently associated with high ferroportin expression in
the livers of iron-loaded mice [119]. Conversely, the lack of
IRE in the alternative ferroportin transcript, which is enriched
in duodenal enterocytes and erythroid precursor cells [118],
allows the accumulation of ferroportin in these tissues during
iron deﬁciency [119,120] by evading the translational blockade
imposed by active IRPs. In an iron-deﬁcient state, the bypass of
the IRE–IRP system contributes to homoeostatic adaptation by
(i) probably facilitating dietary-iron absorption in the duodenum,
and(ii)possiblyalsopermittingefﬂuxofironfromerythroidcells
inthebloodstreamtorestricterythropoiesisandtomakethemetal
available to iron-starved non-erythroid cells. The irradiation-
induced deletion of 58 bp from mouse ferroportin IRE has been
associated with diverse phenotypes, ranging from erythropoietin-
dependent polycythaemia in heterozygous animals to microcytic
hypochromic anaemia in homozygous counterparts [121]. These
results may indicate further complexity in the post-transcriptional
regulation of ferroportin by the IRE–IRP system.
More recently, a high-throughput biochemical screen revealed
an atypical IRE in the 5
 UTR of HIF-2α mRNA that functions
as a translational control element [122]. In vitro, HIF-2α IRE
interacts efﬁciently with recombinant IRP1 and IRP2 [122],
but it appears to be a preferential target of IRP1 in cells
[123,124]. Importantly, HIF-2α regulates hepatic erythropoietin
production [125] and its ablation is associated with anaemia
[126]. Thus translational inhibition of HIF-2α mRNA by IRP1
may lead to reduced erythropoietin expression, which can be
viewedasahomoeostaticresponsetocurtailerythropoiesisiniron
deﬁciency.SinceHIF-2αmediatesthetranscriptionalactivationof
duodenal DMT1 and Dcytb in iron deﬁciency [39,40], its transla-
tional regulation by the IRE–IRP system is also predicted to ﬁne-
tune dietary-iron absorption. The development of animal models
withdisruptedHIF-2α IREcouldprovideavaluabletooltoclarify
the physiological role of IRPs in HIF-2α regulation.
Other experiments resulted in the identiﬁcation of single IRE
motifs in the 3
 UTR of mRNA splice variants encoding MRCKα
[myotonic dystrophy kinase-related Cdc42 (cell division cycle
42)-binding kinase α] [127] and human Cdc14A phosphatase
[127,128].Preliminarybiochemicalcharacterizationsuggeststhat
these IRE motifs contribute to the regulation of mRNA stability,
linking the IRE–IRP system with cytoskeletal remodelling and
the cell cycle. Nevertheless, these IREs do not exhibit extensive
phylogenetic conservation and appear to be restricted to primates
and some mammals [108]. The mRNA encoding β-APP harbours
a non-canonical IRE motif with a conserved 5
 -CAGAG-3
 
sequence(theunderlinedCandGresiduesformabasepair)aspart
of an extended loop in its 5
 UTR, which preferentially interacts
with IRP1 and functions as a translational control element
[129]. Interestingly, α-synuclein mRNA also contains a predicted
IRE-like motif [130] that awaits functional characterization.
Aberrant expression of β-APP and α-synuclein is associated with
Alzheimer’sandParkinson’sdiseasesrespectively;thusvalidation
of the regulatory function of their IREs may couple the IRE–IRP
system with human neurodegenerative conditions.
An extensive phylogenetic analysis conﬁrmed that IRE-
containing mRNAs are exclusively found in metazoans [108].
The ferritin IRE motif may represent the ancestral prototype,
which was subsequently adopted during evolution by other
genes in higher organisms. Notably, IRE-like sequences with
iron-regulatory functions are present in some bacterial mRNAs
[131–133]; however, their modes of action are only distally
reminiscent of the metazoan IRE–IRP network.
Overall, as illustrated in Figure 4, functional IRE motifs have
thus far been identiﬁed in mRNAs encoding proteins of iron
uptake (TfR1), storage (H- and L-ferritin), erythroid utilization
(ALAS2) and transport (DMT1 and ferroportin), as well as
energy metabolism (m-aconitase and Drosophila SDH), hypoxic
regulation (HIF-2α), cytoskeletal reorganization (MRCKα), cell-
cycle control (Cdc14A) and neuronal function (β-APP and
α-synuclein). It is also worth noting that the mRNAs encoding
TfR2, mitochondrial ferritin and ALAS1 do not possess an IRE.
The expanded list of IRE-containing mRNAs emphasizes the role
of the IRE–IRP system as a master post-transcriptional iron-
regulatory switch, but also implies further regulatory potential
outside the context of iron metabolism in a strict sense.
IRPs: FUNCTIONAL AND STRUCTURAL FEATURES
IRP1 and IRP2 do not share sequence similarities with known
RNA-binding proteins and do not contain any established RNA-
bindingmotifs.TheybothbelongtothefamilyofISCisomerases,
which includes m-aconitase [105–107]. This enzyme catalyses
the isomerization of citrate to iso-citrate via the intermediate
cis-aconitate during the citric acid cycle, and contains a cubane
[4Fe–4S]
2+ ISC in its active site. Three of the iron atoms are
attached to cysteine residues of the polypeptide, whereas the
fourth iron (Fea) remains free and mediates catalytic chemistry.
IRP1 assembles an analogous to m-aconitase ISC that converts
it to a c-aconitase (cytosolic aconitase). However, in contrast with
m-aconitase, IRP1 only retains its ISC and its enzymatic function
iniron-repletecells.Inirondeﬁciency,holo-IRP1isconvertedinto
apo-protein that possesses IRE-binding activity. Thus IRP1 is
bifunctional and its mutually exclusive activities are reversibly
regulated by an unusual ISC switch. IRP1 probably evolved
independentlyofm-aconitasefollowinganearlyduplicationevent
that allowed it to acquire IRE-binding activity [134]. A second
duplicationeventledtotheevolutionofIRP2inhighereukaryotes.
IRP2sharesextensivehomologywithIRP1;however,itneither
assembles an ISC nor retains aconitase active-site residues.
Consequently, IRP2 only exhibits an IRE-binding activity and
does not have any enzymatic function. A feature of IRP2 that
distinguishesitfromIRP1isthepresenceofaconservedcysteine-
and proline-rich stretch of 73 amino acids close to its N-terminus.
This sequence is encoded by a separate exon and appears to be
unstructured [135]. IRP2 is regulated in an irreversible manner,
at the level of protein stability.
The crystal structure of IRP1 has been solved in both the
c-aconitase-binding [136] and IRE-binding [137] forms
(Figure 5), although the structure of IRP2 has not yet been
determined. These results have validated earlier evidence that
the site for catalysis and RNA-binding overlap, and the switch
between the enzymatic and RNA-binding forms is associated
with extensive conformational rearrangements. The folding of
holo-IRP1 follows the pattern of m-aconitase [136], despite
relatively limited sequence identity (22%), but consistently with
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Figure 5 Crystal structure of IRP1
(A)c-Aconitaseform(PDBcode2B3X);(B)IRE-bindingform(PDBcode2IPY).Athree-dimensionalstructureofthisFigureisavailableathttp://www.BiochemJ.org/bj/434/0365/bj4340365add.htm.
the conservation of active-site residues. The protein is composed
of four globular domains. Domains 1–3 are compact and join
domain 4 through a surface linker. The ISC is located centrally
at the interface of the four domains. The topology of the ISC and
the surrounding environment are fairly conserved between c- and
m-aconitases. Nevertheless, the overall structure of holo-IRP1,
a protein of 889 amino acids, also shows differences to that of
m-aconitase, which is smaller (780 amino acids). The short IRP1
fragments that do not superimpose with m-aconitase are exposed
on the surface of the protein. As a result, the shapes and surface
topologies of holo-IRP1 and m-aconitase diverge substantially,
which may explain the fact that only the former can acquire IRE-
binding activity.
The structure of IRP1 in a complex with ferritin IRE (at 2.8 Å
resolution) uncovered the details of the protein reorganization
upon loss of its ISC [137]. The main features are a rotation of
domain4by32◦,butalsoanunpredictedextensiverearrangement
of domain 3 by 52◦ that creates a hydrophilic cavity and allows
access to the IRE. The RNA–protein interaction requires two
crucial segments at the interface of domain 2 (residues 436–442)
and domain 3 (residues 534–544). Thr
438 and Asn
439 make direct
contactswiththeIRE.TheterminalresiduesoftheIREloop,A15,
G16 and U17, interact with Ser
371,L y s
379 and Arg
269 respectively
within a cavity between domains 2 and 3. A second binding
site is formed around the unpaired-C-bulge residue between the
upper and lower stem, which occupies a pocket within domain 4,
sandwiched between Arg
713 and Arg
780. The IRE–IRP1 complex
is stabilized by additional bonds, ionic interactions and van der
Waals contacts.
The structural studies described above offered detailed insights
intothedualfunctionofIRP1asac-aconitaseandanIRE-binding
protein. These ﬁndings also enabled the modelling of IRP2
structure and the design of site-directed mutagenesis experiments
to investigate the role of single amino acid residues of IRP2 in
IRE binding [138]. Nevertheless, the crystallization of IRP2 and
the resolution of its structure, especially in a complex with IRE,
will be necessary to precisely map the RNA–protein interaction
andtounderstandthetopologyoftheIRP2-speciﬁc73aminoacid
insert and its possible role in IRE binding.
IRON-DEPENDENT REGULATION OF IRP1
The ISC of IRP1 is the major site for its regulation (Figure 6).
In vitro, holo-IRP1 can be easily reconstituted upon incubation
of apo-IRP1 with ferrous salts, sulﬁde and reducing agents
[139]. Within cells, the conversion of apo- to holo-IRP1 requires
several cofactors, such as the mitochondrial proteins Nfs1 (ISCS)
[140–142], frataxin [143,144], ISCU [145], Grx5 [114,115],
ISD11 [146] or Abcb7 [147], as the silencing of these proteins
favours expression of IRP1 in the IRE-binding form due to
impaired ISC biogenesis. These results support an active role
of mitochondria in the assembly of holo-IRP1. Moreover,
mitochondrial ATP production is required for maintenance and
repair of the IRP1 ISC [148], and ATP binds directly to IRP1
and promotes ISC stabilization [149]. Cytosolic homologues of
Isu/ISCU and Nfs1/ISCS [145,150], as well as the cytosolic
proteins Cfd1 [151], Nbp35 [152], Nar1/IOP1 [153], Cia1 [154],
Dre2[155]and,possibly,Tah18,whichtransferselectronstoDre2
[156], are also implicated in the ISC assembly of IRP1.
Iron starvation leads to conversion of holo-IRP1 into an IRE-
binding apo-protein following depletion of its ISC. In cultured
cells, this process is relatively lengthy (8–12 h) and does not
require de novo protein synthesis. IRP1 is a fairly stable protein
(half-life of ∼24 h) and, under normal circumstances, its stability
remains unaffected by iron levels. However, when ISC biogenesis
is impaired by either inactivation of ISC assembly cofactors or
phosphorylationofIRP1atSer
138,ironleadstoubiquitinationand
slow degradation of apo-IRP1 by the proteasome [142,157,158].
This backup mechanism prevents accumulation of excessive apo-
IRP1iniron-loadedcellsthatmaydisruptironhomoeostasisbyits
unregulated IRE-binding activity. Iron-chelating drugs promote
considerably more efﬁcient conversion of holo- to apo-IRP1 in
typical cell-culture conditions with 21% oxygen, as compared
with lower oxygen concentrations (3–6%) that are more relevant
physiologically in tissues [159]. This is consistent with the
predominance of holo-IRP1 in tissues of iron-deﬁcient animals,
and the conversion of only a small fraction to an IRE-binding
apo-protein. The ISC of IRP1 exhibits sensitivity to oxidants (see
below), whereas hypoxia favours its stabilization [123,160].
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Figure 6 Under physiological conditions, IRP1 is regulated by a reversible ISC switch
Iron deﬁciency promotes ISC disassembly and a conformational rearrangement, resulting in the conversion of IRP1 from c-aconitase to an IRE-binding protein. The ISC is regenerated in iron-replete
cells. Hypoxia favours maintenance of the ISC, whereas H2O2 or NO promote its disassembly. When the ISC-biogenesis pathway is not operational, iron leads to ubiquitination of apo-IRP1 by the
FBXL5 E3 ligase complex (including Skp1, Cul1 and Rbx1), resulting in proteasomal degradation.
IRP1 can be phosphorylated by PKC (protein kinase C) at
the conserved Ser
138 and Ser
711 residues [139,157,161]. Ser
138
is located in proximity to the ISC and its phosphorylation
appears to interfere with the ISC stability and alter the set-
point for its disassembly in an oxygen-dependent manner [160].
The introduction of a phosphomimetic S138E mutation favours
non-oxidative demetallation of [4Fe–4S]
2+ to [3Fe–4S]
0 by
iron-chelating drugs in vitro [160] and sensitizes IRP1 to iron-
dependent degradation in cells [157,158]. Phosphorylation of the
C-terminal Ser
711 may also regulate IRP1 functions. An S711E
substitutioninhibitsthecapacityofIRP1toconvertcitrateintothe
intermediate cis-aconitate in vitro [139,161] and impairs its IRE-
binding activity in cells [139]. PKC-mediated phosphorylation
has been reported to promote the translocation of IRP1 from the
cytosol to the ER and Golgi in iron-deﬁcient cells, probably to
facilitate its interaction with TfR1 IREs [162].
IRON-DEPENDENT REGULATION OF IRP2
IRP2 is synthesized de novo in response to low iron and remains
stable under iron-starvation or hypoxia [105–107]. In iron-
replete cells, however, IRP2 becomes destabilized and undergoes
rapid ubiquitination and degradation by the proteasome. Earlier
assumptions that the stability of IRP2 is regulated by its speciﬁc
73aminoacidinserthavebeenexperimentallyrejected[163,164].
The analysis of a series of IRP2 deletion mutants provided
evidencethatitsC-terminuscontainssequencesthatarenecessary,
but not sufﬁcient, for iron-dependent degradation [165]. These
results suggested that the recognition of IRP2 by the proteasomal
degradation machinery may require additional IRP structural
elements. DMOG (dimethyl-oxalyl-glycine), an inhibitor of
2-oxoglutarate-dependent oxygenases, partially stabilizes IRP2
against iron, suggesting a possible involvement of this family
of enzymes in tagging IRP2 for degradation [163,164]. Similar
effects were observed within cells treated with succinylacetone,
aninhibitorofhaemsynthesis,[166–168],highlightingapotential
role of endogenous haem in the control of IRP2 stability.
More recent results demonstrated that IRP2 (as well as apo-
IRP1) are substrates of FBXL5 (F-box and leucine-rich repeat
protein 5), a member of an E3 ubiquitin ligase complex that
also includes Skp1 (S-phase kinase-associated protein 1), Cul1
(Cullin 1) and Rbx1 (Ring-box 1) [169,170]. FBXL5 contains an
N-terminal haemerythrin domain with a characteristic Fe–O–Fe
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Figure 7 Iron and oxygen-dependent regulation of IRP2 stability by FBXL5
IRP2 is stable in iron deﬁcient and/or hypoxic cells; under these conditions, FBXL5 undergoes ubiquitination and proteasomal degradation. An increase in iron and oxygen levels stabilizes FBXL5
by formation of an Fe–O–Fe centre in its haemerythrin domain, triggering the assembly of an E3 ubiquitin ligase complex together with Skp1, Cul1 and Rbx1. This complex ubiquitinates (Ub) IRP2,
leading to its recognition by the proteasome and its degradation.
centre. Notably, FBXL5 is the ﬁrst mammalian protein identiﬁed
to harbour this ancient domain, which is used by oxygen-
transport proteins in some bacteria and lower eukaryotes [171].
In iron-replete and oxygenated cells, FBXL5 accumulates and
interacts with IRP2, mediating its ubiquitination and subsequent
degradation (Figure 7). In contrast, in iron-deﬁcient or hypoxic
cells, FBXL5 itself undergoes proteasomal degradation by a yet
unknown mechanism upon the loss of its Fe–O–Fe centre, which
allows the stabilization of IRP2. Deletion of the haemerythrin
domain or mutation of iron-binding ligands abolishes the
regulatory function of FBXL5. Hence, FBXL5 senses iron and
oxygen levels through the Fe–O–Fe centre of its haemerythrin
domain and emerges as a novel regulator of cellular iron
homoeostasis.
IRP2 can be phosphorylated at Ser
157 by Cdk1 (cyclin-
dependent kinase 1)/cyclin B1 during the G2/M-phase of the
cell cycle; this response decreases its IRE-binding activity and
derepresses ferritin mRNA translation [172]. During mitotic
exit, Ser
157 undergoes dephosphorylation by the phosphatase
Cdc14A. The regulation of Cdc14A during the cell cycle was
found to be iron independent, despite the presence of the IRE
motif in one of its mRNA splice variants. The stimulation of
ferritin synthesis coupled to the inactivation of phosphorylated
IRP2 is thought to protect DNA from iron-catalysed oxidative
damage.
REDOX REGULATION OF IRON METABOLISM
Both IRP1 and IRP2 are sensitive to ROS and RNS (reactive
nitrogen species) (reviewed in [173]). The redox regulation of
IRP1 is mediated by its ISC. Exposure of cells to micromolar
concentrations of H2O2 leads to removal of the ISC and induction
of IRP1 for IRE binding via an incompletely characterized
signalling mechanism. This response can be antagonized by
myeloperoxidase-derived hypochlorite [174]. In vitro,R O Sa n d
RNS remove the Fea of the ISC and convert [4Fe–4S]
2+-IRP to
[3Fe–4S]
2+-IRP1, which is non-functional. IRP1 also responds
to NO, which likewise induces IRE binding at the expense of
its aconitase activity, albeit by a diverse mechanism. NO may
destroy the ISC of IRP1, but also promote iron efﬂux from cells
[175], suggesting that the NO-mediated switch of IRP1 to its
IRE-binding form could represent a homoeostatic response to
iron starvation.
Consistent with this hypothesis, NO released from transfected
ﬁbroblasts was found to stabilize IRP2 in co-cultured cells
[176]. The ﬁrst hints for redox regulation of IRP2 were
provided by experiments showing that antioxidants, such
as ascorbate, α-tocopherol and N-acetylcysteine promote the
proteasomal turnover of IRP2 [164]. More recently, it was shown
that oxidants stabilize previously induced IRP2 against iron-
dependent degradation [176a]. On the other hand, ROS may also
oxidize Cys
512 and Cys
516, predicted to lie within the IRE-binding
cleft of IRP2. Formation of a disulﬁde bridge between these two
cysteine residues was shown to inhibit the IRE-binding activity
of IRP2 and reduce TfR1 mRNA abundance [138].
The well documented induction of IRP1 by oxidative stress
modulates cellular iron metabolism. Thus H2O2 leads to
transient inhibition of ferritin synthesis, up-regulation of TfR1,
increased uptake of
59Fe-labelled Tf and, notably, elevated
storage of
59Fe into ferritin, despite the decrease in the ferritin
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content [177]. Oxidative stress may also regulate cellular
iron metabolism independently of IRPs, as sustained non-
toxic H2O2 concentrations (<5 μM), which mimic inﬂammatory
conditions and do not affect IRE-binding activity, stimulate
TfR1 mRNA translation [178]. Moreover, higher H2O2 doses
promote proteasomal degradation of ferritin [179]. Importantly,
ROS stabilize HIF-α subunits by oxidizing Fe
2+ to Fe
3+ and
thereby depleting an essential cofactor of prolyl hydroxylases,
which initiate their degradation in normoxia [180]. This has
profound implications for iron metabolic pathways, considering
that HIF transcriptionally regulates DMT1, Dcytb, Tf, TfR1,
ceruloplasmin, HO-1 and ALAS2 [39,181,182]. The ROS-
dependent repression of hepcidin via C/EBPα [36,183,184]
further highlights the multitude of pathways for redox regulation
of iron metabolism.
PHYSIOLOGICAL FUNCTIONS OF IRP1 AND IRP2
Targeted disruption of both IRP1 and IRP2 is incompatible with
life and leads to embryonic lethality at the blastocyst stage
[185], illustrating the importance of these proteins in early
development. Mice with tissue-speciﬁc ablation of both IRP1
a n dI R P 2h a v eb e e ng e n e r a t e db yC r e / loxP technology. In the
intestine, the lack of IRPs is associated with growth defects, in-
testinal malabsorption, dehydration, weight loss and death within
4 weeks of birth [186]. The deregulated expression of TfR1,
ferritin,ferroportinandDMT1isconsistentwithacriticalfunction
of IRPs in intestinal iron transport and storage. The lack of
IRPs in hepatocytes also leads to premature death due to liver
failure, mitochondrial disfunction and alterations in haem and
ISC biosynthetic pathways [187].
Single IRP1
−/− or IRP2
−/− mice are viable, indicating a
functional redundancy of the ubiquitously expressed IRP1 and
IRP2. Nonetheless, it appears that IRE-containing mRNAs are
primarily regulated by IRP2 in vivo, as IRP1 is predominantly
expressed as c-aconitase within tissues [105,188]. Hence, it is
not surprising that IRP1
−/− mice do not exhibit any overt
pathological phenotype under standard laboratory conditions,
and merely misregulate TfR1 and ferritin expression in the
kidney and brown fat [189]. IRP1
−/− mice also mount an
efﬁcientinﬂammatorysignallingresponsetoturpentine[190]and
do not exhibit differential sensitivity to anthracycline-induced
cardiotoxicity compared with wild-type animals [191]. The
lack of any discernible pathology in IRP1
−/− mice may raise
questionsonthephysiologicalsigniﬁcanceofIRP1asc-aconitase.
Considering the important roles of citrate in metabolism [192],
it will be important to examine IRP1
−/− animals for potential
metabolic defects.
IRP2
−/− mice develop microcytic hypochromic anaemia,
manifest excessive iron deposition in the duodenum and the
liver and have relative iron deﬁciency in the spleen [193,194].
Erythroid precursor cells of IRP2
−/− animals exhibit reduced
TfR1 expression, which may account for the decreased iron
levels in the bone marrow. These cells also contain high levels
ofprotoporphyrinIX,apparentlyduetounrestrictedexpressionof
ALAS2, which is reminiscent of erythropoietic protoporphyria.
The characterization of mice with tissue-speciﬁc disruption of
IRP2 in either enterocytes, hepatocytes or macrophages showed
that the deregulation of tissue iron levels during ubiquitous IRP2
deﬁciency is largely explained by cell-autonomous functions
of IRP2 [195]. Thus selective ablation of IRP2 in enterocytes,
hepatocytes or macrophages impairs iron homoeostasis in these
cells,butdoesnotalterhaematologicalorplasmaironparameters,
suggesting that the microcytosis of IRP2
−/− mice is caused by
an intrinsic defect in haematopoiesis.
ThedisruptionofIRP2hasalsobeenassociatedwithneuropath-
ology. Aging IRP2
−/− mice accumulate excessive amounts of
ironinspeciﬁcareasofthebrainanddevelopaprogressiveneuro-
degenerativedisorder[196,197].Thisclinicalphenotypeisfurther
aggravated in a genetic background of IRP1 haploinsufﬁciency
(IRP2
−/− IRP1
+/− mice)[198].TreatmentofIRP2
−/− micewith
theISC-disrupting nitroxideTempolpartially rescuedneuropathy
in these animals, due to activation of endogenous IRP1 for IRE
binding [199]. However, Tempol failed to correct microcytosis,
possibly due to lower expression of IRP1 in erythroblasts com-
pared with the forebrain. Interestingly, isogenic IRP2
−/− mice
generated by a different targeting strategy do not manifest severe
neurodegeneration, but perform relatively poorly in neurobehav-
ioural tests [200]. The role of IRP2 in neuronal physiology is
unclear. It has been hypothesized that disruption of iron homoeo-
stasis in neurons of IRP2
−/− animals (which show suppression
of TfR1 and unrestrained expression of ferritin and, possibly, also
ferroportin) may cause a state of functional iron deﬁciency [105].
In addition, the lack of IRP2 may trigger a decrease in brain
copper levels by derepressing translation of the IRE-containing
β-APP mRNA, which is also implicated in copper efﬂux [201].
Taken together, the results obtained from the analysis of
currently available IRP knockout mice demonstrate an essential
role of the IRE–IRP system in body iron homoeostasis. Further
characterizationoftheseanimals,aswellasthegenerationofnew
models,e.g.bearingspatialand/ortemporaldisruptionofIRPs,or
engineered for tissue-speciﬁc expression of constitutive mutants,
is expected to improve our understanding on the function of the
IRE–IRP network in health and disease.
IRPs AND CANCER
There is evidence for possible involvement of IRPs in cancer
biology. The overexpression of wild-type IRP1 or IRP1C437S,a
mutant with constitutive IRE-binding activity, in human H1299
lung cancer cells did not affect their proliferation in culture, but
signiﬁcantly impaired the growth of tumour xenografts formed
upon injection of these cells into nude mice [202]. In contrast, in
a similar setting, the overexpression of IRP2 strongly accelerated
tumour xenograft growth, and this apparent pro-oncogenic
activity was abolished by deletion of the IRP2-speciﬁc domain of
73 amino acids [203]. Interestingly, these contrasting phenotypes
were not associated with differential expression of known IRP
targets. In fact, ferritin evaded the suppressor activity of both
IRP1andIRP2transgenesinthetumourxenografts,aspreviously
s h o w ni nd e n s ec u l t u r e so fI R P 1 C437S-overexpressing cells [204].
IRP1- and IRP2-overexpressing tumours exhibited distinct gene-
expression proﬁles, suggesting that IRPs may differentially
modulate cancer growth by mechanisms independent of their
function as IRE-binding proteins. The pro-oncogenic activity
of IRP2 correlated with increased ERK1/2 (extracellular-signal-
regulated kinase 1/2) phosphorylation and high levels of
c-myc,whichisparticularlyintriguingconsideringthatthisproto-
oncogene transcriptionally activates IRP2 [205]. Further work
is required to understand the molecular basis underlying the
apparent tumour suppressor activity of IRP1 and to elucidate
whether IRP2 functions as a bona ﬁde oncogene and, possibly,
participates in a feedback regulatory loop with c-myc to control
tumour growth.
PERSPECTIVES
Until the mid-1980s, the bio-iron ﬁeld was restricted to the
study of Tf, TfR1 and ferritin. The subsequent discovery of
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the IRE–IRP system prepared the way for understanding the
co-ordinate regulation of cellular iron metabolism. In the new
millennium, the identiﬁcation of hepcidin as a master hormonal
switchofsystemicironhomoeostasishasprovidedaframeworkto
comprehend the regulation of physiological mechanisms for iron
trafﬁc in the body and to decipher the molecular basis underlying
variousiron-relateddisorders.Today,anin-depthcharacterization
of the signalling pathways and cross-talk activities culminating in
the activation of hepcidin continues to pose a major challenge.
This includes elucidation of the early responses to systemic
iron perturbations or alterations in erythropoietic activity that
translate into hepcidin regulation. It should also be noted that the
profoundbiomedicalimplicationsassociatedwiththemodulation
of hepcidin pathways render the hepcidin–ferroportin axis an
attractive target for drug development.
It will be important to further characterize and better
understand the regulatory links between systemic and cellular
iron metabolism. For example, the post-transcriptional regulation
of ferroportin and HIF-2α by IRPs is of particular interest,
considering that the former is the target of hepcidin, whereas the
latterisanupstreamregulatoroferythropoiesisandintestinaliron
absorption. Moreover, TfR1, a target of IRPs, is crucial for iron-
dependent regulation of hepcidin. Future work is also expected
to clarify the role of the IRE–IRP system in neuronal biology,
in light of the biochemically characterized non-canonical IRE
and the predicted IRE in the mRNAs encoding β-APP and α-
synuclein respectively. It is also conceivable that additional IRE-
containing mRNAs, especially with atypical IRE motifs, remain
to be discovered. Although studies of IRP knockout animals have
provided crucial insights into the role of the IRE–IRP regulatory
system in vivo, the physiological signiﬁcance of an IRE motif
in the regulation of a given mRNA could be better appreciated
by generating animals with speciﬁc disruption of this motif, to
uncouple mRNA expression from the control of IRPs.
Several outstanding questions on cellular iron metabolism,
primarily related to the movement of iron across organelles, await
further investigation. Future work will probably shed light on the
roles of the siderophore 2,5-DHBA, Grx3 and Grx4, PCBP1 and
the E3 ubiquitin ligase FBXL5 in intracellular iron sensing
andtrafﬁcking,andontherolesofABCandSLCtransportersand
ofFLVCRinthetransportofhaemanditsprecursors.Therapidly
growing ﬁeld of ISC biogenesis is expected to provide novel
links between cellular iron metabolism and utilization, and the
identiﬁcation of iron-regulatory pathways involving microRNAs
may also be anticipated. Finally, characterization of the roles of
IRP1 and IRP2 in cancer biology may uncover novel functions
for these proteins, not necessarily related to iron metabolism.
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